Next Article in Journal / Special Issue
Long Non-Coding RNAs in Liver Cancer and Nonalcoholic Steatohepatitis
Previous Article in Journal / Special Issue
Comparison of Poly-A+ Selection and rRNA Depletion in Detection of lncRNA in Two Equine Tissues Using RNA-seq
Open AccessFeature PaperReview

Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?

by 1,2,*, 1,2 and 1,3
1
The Florey Institute for Neuroscience and Mental Health, Parkville, The University of Melbourne, Melbourne, Victoria 3052, Australia
2
The Department of Psychiatry, Monash University, 27-31 Wright Street, Clayton, Victoria 3168, Australia
3
The Centre for Mental Health, Swinburne University of Technology, Hawthorn, Victoria 3122, Australia
*
Author to whom correspondence should be addressed.
Non-Coding RNA 2020, 6(3), 33; https://doi.org/10.3390/ncrna6030033
Received: 25 June 2020 / Revised: 20 August 2020 / Accepted: 20 August 2020 / Published: 24 August 2020
(This article belongs to the Collection Feature Papers in Non-coding RNA)
The similarities between the depressive symptoms of Major Depressive Disorders (MDD) and Bipolar Disorders (BD) suggest these disorders have some commonality in their molecular pathophysiologies, which is not apparent from the risk genes shared between MDD and BD. This is significant, given the growing literature suggesting that changes in non-coding RNA may be important in both MDD and BD, because they are causing dysfunctions in the control of biochemical pathways that are affected in both disorders. Therefore, understanding the changes in non-coding RNA in MDD and BD will lead to a better understanding of how and why these disorders develop. Furthermore, as a significant number of individuals suffering with MDD and BD do not respond to medication, identifying non-coding RNA that are altered by the drugs used to treat these disorders offer the potential to identify biomarkers that could predict medication response. Such biomarkers offer the potential to quickly identify patients who are unlikely to respond to traditional medications so clinicians can refocus treatment strategies to ensure more effective outcomes for the patient. This review will focus on the evidence supporting the involvement of non-coding RNA in MDD and BD and their potential use as biomarkers for treatment response. View Full-Text
Keywords: mood disorders; major depressive disorder; bipolar disorder; antidepressants; mood stabilisers; miRNA; lncRNA; Biomarkers mood disorders; major depressive disorder; bipolar disorder; antidepressants; mood stabilisers; miRNA; lncRNA; Biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Gibbons, A.; Sundram, S.; Dean, B. Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers? Non-Coding RNA 2020, 6, 33.

AMA Style

Gibbons A, Sundram S, Dean B. Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers? Non-Coding RNA. 2020; 6(3):33.

Chicago/Turabian Style

Gibbons, Andrew; Sundram, Suresh; Dean, Brian. 2020. "Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?" Non-Coding RNA 6, no. 3: 33.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop